Dendreon Corporation (NDAQ:DNDN) shares moved up $0.27, or 4.42%, to $6.34 today after the company announced new study data on Provenge at the American Urological Association on Sunday. The company's board also agreed to layoff 40 workers in an effort to reduce its cash burn rate while it works towards FDA approval. The news comes after an extremely volatile couple of months for the company, whose shares ranged between $3.57 and $25.25.

The new study data on Provenge was disclosed in the abstract "Advanced Prostate Cancer Patients who Receive Sipuleuc-T followed by Docetaxel Have Prolonged Survival" authored by Daniel Petrylak, MD. According to Petrylak, the results of the 82-patient study have suggested that the use of Provenge as a first-line treatment followed by chemotherapy docetaxel upon disease progression may provide patients with substantially prolonged survival benefits.

Dendreon also has strong support from patients who have begun lobbying the FDA to get Provenge approved. In fact, a small group of prostate cancer patients are meeting the FDA Commissioner during the next few months to discuss the matter. Meanwhile, they have setup ProvengeNow.org in an effort to attract further interest from patients to help their cause.

Many doctors that attended the American Urological Association's meeting today (during which Provenge was supposed to be launched) also indicated their disappointment. Many of their patients had been anticipating the new drug and were extremely disappointed when the FDA decided to delay their ruling by several months to a year. Whether or not any of these efforts materialize in the form of a quicker approval remains to be seen; however, DNDN is definitely a stock with great upside potential once Provenge hits the market. Combined, these factors make DNDN a stock worth watching!

Related Companies
Cell Genesys, Inc. (CEGE)
AVI BioPharma, Inc. (AVII)
MannKind Corporation (MNKD)